Brian McClune is an Oncology physician affiliated with University of Utah. OpenAlex indexes 135 publications with 3,117 citations (h-index 23).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1950 Circle Of Hope Dr
Salt Lake City, UT 841125500
Telephone
801-585-0100Provider last certified this registry record 20 Nov 2021.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- National Marrow Donor ProgramProgram year20253 payments
- Daiichi Sankyo Inc.Program year20251 payment
- Incyte CorporationProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
32.6%Thalidomide Analog32.6%Revlimid80%Pomalyst20%Part D≥39 patientsDermatology
19.5%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor19.5%Acyclovir100%Part D≥35 patientsMetabolism & gastrointestinal
17.5%Proton pump inhibitor9%Omeprazole100%Part D≥18 patientsPotassium supplement4.2%Potassium Chloride100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Access barriers to hematopoietic stem cell transplantation and CAR T-cells in US
Leukemia & lymphoma/Leukemia and lymphoma
2025 - Time‐to‐event surrogate end‐points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis
British Journal of Haematology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Colman, MD
University of Utah
Michael Varner, MD
University of Utah
James Fang
University of Utah
Wallace Akerley, MD
University of Utah
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”